Therefore, the European Society for Medical Oncology (ESMO) recommends the S100B protein as a blood test marker in the follow-up of melanoma patients, pointing out that increased levels of serum S100B protein have both high specificity for disease progression and a significant role in monitoring stage III and IV melanoma patients and in the prognosis of the disease [18]. The gene discussed is S100B; the disease is melanoma.